Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C0251006 – PF-06823859 in active idiopathic inflammatory myopathies
2022-502739-20-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in dermatomyositis (DM) and Autoimmune Myopathies comparing PF-06823859 (dazukibart) + standard-of-care with Placebo + standard-of-care (2 arms). Planned start Oct 2023; status: authorised.
02
Drugs
dazukibart
03
Conditions
dermatomyositis (DM)Autoimmune Myopathies
Beyond the preview
Go deeper on 2022-502739-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502739-20-00.